Leukotrienes as modifiers of preclinical atherosclerosis?

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Riccioni, Graziano ^a   Bäck, Magnus ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; EARLY GROWTH RESPONSE FACTOR 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE D4; LEUKOTRIENE E4; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONTELUKAST; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; THEOPHYLLINE; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VELIFLAPON; VON WILLEBRAND FACTOR; PLACEBO;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AORTA STENOSIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CAROTID ARTERY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFLAMMATION; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; METABOLISM; MOUSE; RISK;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LEUKOTRIENES; MICE; MODELS, BIOLOGICAL; PLACEBOS; RISK;

EID: 84862317987     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/490968     Document Type: Review

References (75)

1. Libby P., Inflammation in atherosclerosis Nature 2002 420 6917 868 874 (Pubitemid 36019640)
2. Arsenault B. J., Boekholdt S. M., Kastelein J. J. P., Lipid parameters for measuring risk of cardiovascular disease Nature Reviews Cardiology 2011 8 4 197 206
3. Huo Y., Xia L., P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall Trends in Cardiovascular Medicine 2009 19 4 140 145
4. Miller M., An emerging paradigm in atherosclerosis: focus on subclinical disease Postgraduate Medicine 2009 121 2 49 59
5. Funk C. D., Leukotriene inflammatory mediators meet their match Science Translational Medicine 2011 3 66, article 66ps3
6. Sampson A. P., FLAP inhibitors for the treatment of inflammatory diseases Current Opinion in Investigational Drugs 2009 10 11 1163 1172
7. Keppler D., Leukotrienes: biosynthesis, transport, inactivation, and analysis Reviews of Physiology Biochemistry and Pharmacology 1992 121 1 30
8. Samuelsson B., The discovery of the leukotrienes American Journal of Respiratory and Critical Care Medicine 2000 161 2 S2 S6
9. Samuelsson B., Dahlen S. E., Lindgren J. A., Leukotrienes and lipoxins: structures, biosynthesis, and biological effects Science 1987 237 4819 1171 1176 (Pubitemid 17131222)
10. Bck M., Dahlen S. E., Drazen J. M., Evans J. F., Serhan C. N., Shimizu T., Yokomizo T., Rovati G. E., International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions Pharmacological Reviews 2011 63 3 539 584
11. Okuno T., Iizuka Y., Okazaki H., Yokomizo T., Taguchi R., Shimizu T., 12(S)-hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2 Journal of Experimental Medicine 2008 205 4 759 766 (Pubitemid 351549875)
12. Funk C. D., Prostaglandins and leukotrienes: advances in eicosanoid biology Science 2001 294 5548 1871 1875 (Pubitemid 33101574)
13. Vigorito C., Giordano A., Cirillo R., Genovese A., Rengo F., Marone G., Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man International Journal of Clinical and Laboratory Research 1997 27 3 178 184
14. Capra V., Thompson M. D., Sala A., Cole D. E., Folco G., Rovati G. E., Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends Medicinal Research Reviews 2007 27 4 469 527 (Pubitemid 46984658)
15. Chrissobolis S., Miller A. A., Drummond G. R., Kemp-Harper B. K., Sobey C. G., Oxidative stress and endothelial dysfunction in cerebrovascular disease Frontiers in Bioscience 2011 16 5 1733 1745
16. Bck M., Bu D. X., Brnstrm R., Sheikine Y., Yan Z. Q., Hansson G. K., Leukotriene B4 signaling through NF- B-dependent BLT 1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia Proceedings of the National Academy of Sciences of the United States of America 2005 102 48 17501 17506 (Pubitemid 41740895)
17. Qiu H., Johansson A.-S., Sjstrm M., Wan M., Schrder O., Palmblad J., Haeggstrm J. Z., Differential induction of BLT receptor expression on human endothelial cells by lipopolysacharide, cytokines, and leukotriene B 4 Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 6913 6918
18. Bck M., Qiu H., Haeggstrm J. Z., Sakata K., Leukotriene B 4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor American Journal of Physiology 2004 287 1 56-1 H419 H424
19. Bck M., Sakata K., Qiu H., Haeggstrm J. Z., Dahlén S. E., Endothelium-dependent vascular responses induced by leukotriene B 4 Prostaglandins and Other Lipid Mediators 2007 83 3 209 212 (Pubitemid 46661260)
20. Mita H., Hasegawa M., Saito H., Akiyama K., Levels of cysteinyl leukotriene receptor mrna in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mrna in eosinophils Clinical and Experimental Allergy 2001 31 11 1714 1723 (Pubitemid 34204428)
21. Gronert K., Martinsson-Niskanen T., Ravasi S., Chiang N., Serhan C. N., Selectivity of recombinant human leukotriene D 4, leukotriene B 4, and lipoxin A 4 receptors with aspirin-triggered 15-epi-LXA 4 and regulation of vascular and inflammatory responses American Journal of Pathology 2001 158 1 3 9 (Pubitemid 32096464)
22. Zhang W. P., Hu H., Zhang L., Ding W., Yao H. T., Chen K. D., Sheng W. W., Chen Z., Wei E. Q., Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors Neuroscience Letters 2004 363 3 247 251 (Pubitemid 38746522)
23. Bck M., Leukotriene receptors: crucial components in vascular inflammation TheScientificWorldJournal 2007 7 1422 1439
24. Pedersen K. E., Bochner B. S., Undem B. J., Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism Journal of Pharmacology and Experimental Therapeutics 1997 281 2 655 662 (Pubitemid 27203796)
25. Zhao L., Moos M. P. W., Grbner R., Pédrono F., Fan J., Kaiser B., John N., Schmidt S., Spanbroek R., Ltzer K., Huang L., Cui J., Rader D. J., Evans J. F., Habenicht A. J. R., Funk C. D., The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm Nature Medicine 2004 10 9 966 973 (Pubitemid 39273738)
26. Uzonyi B., Ltzer K., Jahn S., Kramer C., Hildner M., Bretschneider E., Radke D., Beer M., Vollandt R., Evans J. F., Funk C. D., Habenicht A. J. R., Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells Proceedings of the National Academy of Sciences of the United States of America 2006 103 16 6326 6331
27. Yun M. R., Im D. S., Lee S. J., Park H. M., Bae S. S., Lee W. S., Kim C. D., 4-hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase Free Radical Biology and Medicine 2009 46 5 692 698
28. Fair A., Pritchard K. A. Jr., Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activity: induction of 5-lipoxygenase activating protein Biochemical and Biophysical Research Communications 1994 201 2 1014 1020 (Pubitemid 24206973)
29. Rao R. M., Yang L., Garcia-Cardena G., Luscinskas F. W., Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall Circulation Research 2007 101 3 234 247 (Pubitemid 47344073)
30. Hansson G. K., Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease New England Journal of Medicine 2005 352 16 1685 1695
31. Bck M., Sultan A., Ovchinnikova O., Hansson G. K., 5-Lipoxygenase- activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation Circulation Research 2007 100 7 946 949 (Pubitemid 46598919)
32. Leppert D., Hauser S. L., Kishiyama J. L., An S., Zeng L., Goetzl E. J., Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids FASEB Journal 1995 9 14 1473 1481
33. Bck M., Ketelhuth D. F. J., Agewall S., Matrix metalloproteinases in atherothrombosis Progress in Cardiovascular Diseases 2010 52 5 410 428
34. Houard X., Ollivier V., Louedec L., Michel J. B., Bck M., Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B 4 as a major chemotactic factor released from the intraluminal thrombus FASEB Journal 2009 23 5 1376 1383
35. Ketelhuth D. F. J., Bck M., The role of matrix metalloproteinases in atherothrombosis Current Atherosclerosis Reports 2011 13 2 162 169
36. Hlawaty H., Jacob M. P., Louedec L., Letourneur D., Brink C., Michel J. B., Feldman L., Bck M., Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 4 518 524
37. Seo K. W., Lee S. J., Kim C. E., Yun M. R., Park H. M., Yun J. W., Bae S. S., Kim C. D., Participation of 5-lipoxygenase-derived LTB4 in 4-hydroxynonenal-enhanced MMP-2 production in vascular smooth muscle cells Atherosclerosis 2010 208 1 56 61
38. Libby P., Vascular biology of atherosclerosis: overview and state of the art American Journal of Cardiology 2003 91 3, supplement 3 6
39. Szmitko P. E., Wang C.-H., Weisel R. D., De Almeida J. R., Anderson T. J., Verma S., New markers of inflammation and endothelial cell activation part I Circulation 2003 108 16 1917 1923 (Pubitemid 37296533)
40. Ridker P. M., Stampfer M. J., Rifai N., Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease Journal of the American Medical Association 2001 285 19 2481 2485 (Pubitemid 32433842)
41. Riccioni G., Zanasi A., Vitulano N., Mancini B., D'Orazio N., Leukotrienes in atherosclerosis: new target insights and future therapy perspectives Mediators of Inflammation 2009 2009 6
42. Dwyer J. H., Allayee H., Dwyer K. M., Fan J., Wu H., Mar R., Lusis A. J., Mehrabian M., Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis New England Journal of Medicine 2004 350 1 29 37 (Pubitemid 38032181)
43. Iovannisci D. M., Lammer E. J., Steiner L., Cheng S., Mahoney L. T., Davis P. H., Lauer R. M., Burns T. L., Association between a leukotriene C 4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine study Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 394 399 (Pubitemid 46150770)
44. Bck M., Inhibitors of the 5-lipoxygenase pathway in atherosclerosis Current Pharmaceutical Design 2009 15 27 3116 3132
45. Mehrabian M., Allayee H., Wong J., Shih W., Wang X. P., Shaposhnik Z., Funk C. D., Lusis A. J., Identification of 5-Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice Circulation Research 2002 91 2 120 126 (Pubitemid 34827222)
46. Cao R. Y., Amand T. S., Grbner R., Habenicht A. J. R., Funk C. D., Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice Atherosclerosis 2009 203 2 395 400
47. Jawien J., Gajda M., Rudling M., Mateuszuk L., Olszanecki R., Guzik T. J., Cichocki T., Chlopicki S., Korbut R., Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice European Journal of Clinical Investigation 2006 36 3 141 146 (Pubitemid 43341263)
48. Riccioni G., Bck M., Capra V., Leukotrienes and atherosclerosis Current Drug Targets 2010 11 7 882 887
49. Kim N. D., Luster A. D., Regulation of immune cells by eicosanoid receptors TheScientificWorldJournal 2007 7 1307 1328 (Pubitemid 47435438)
50. Jawien J., Korbut R., The current view on the role of leukotrienes in atherogenesis Journal of Physiology and Pharmacology 2010 61 6 647 650
51. Moraes J., Assreuy J., Canetti C., Barja-Fidalgo C., Leukotriene B 4 mediates vascular smooth muscle cell migration through v 3 integrin transactivation Atherosclerosis 2010 212 2 406 413
52. Sakata K., Dahlén S. E., Bck M., The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component British Journal of Pharmacology 2004 141 3 449 456 (Pubitemid 38304892)
53. Heller E. A., Liu E., Tager A. M., Sinha S., Roberts J. D., Koehn S. L., Libby P., Aikawa E. R., Chen J. Q., Huang P., Freeman M. W., Moore K. J., Luster A. D., Gerszten R. E., Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment Circulation 2005 112 4 578 586 (Pubitemid 41060799)
54. Aiello R. J., Brees D., Francone O. L., ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDl formation and inflammation Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 6 972 980 (Pubitemid 36713549)
55. Aiello R. J., Brees D., Bourassa P. A., Royer L., Lindsey S., Coskran T., Haghpassand M., Francone O. L., Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 4 630 637 (Pubitemid 34408745)
56. Subbarao K., Jala V. R., Mathis S., Suttles J., Zacharias W., Ahamed J., Ali H., Tseng M. T., Haribabu B., Role of leukotriene B 4 receptors in the development of atherosclerosis: potential mechanisms Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 2 369 375 (Pubitemid 38197592)
57. Allen S., Dashwood M., Morrison K., Yacoub M., Differential leukotriene constrictor responses in human atherosclerotic coronary arteries Circulation 1998 97 24 2406 2413 (Pubitemid 28278184)
58. Nagy E., Andersson D. C., Caidahl K., Eriksson M. J., Eriksson P., Franco-Cereceda A., Hansson G. K., Bck M., Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts Circulation 2011 123 12 1316 1325
59. Mueller C. F. H., Wassmann K., Widder J. D., Wassmann S., Chen C. H., Keuler B., Kudin A., Kunz W. S., Nickenig G., Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C 4 export Circulation 2008 117 22 2912 2918 (Pubitemid 351787075)
60. Jawien J., Gajda M., Wokow P., Zuraska J., Olszanecki R., Korbut R., The effect of montelukast on atherogenesis in apoE/LDLRdouble knockout mice Journal of Physiology and Pharmacology 2008 59 3 633 639
61. Kaetsu Y., Yamamoto Y., Sugihara S., Matsuura T., Igawa G., Matsubara K., Igawa O., Shigemasa C., Hisatome I., Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro Cardiovascular Research 2007 76 1 160 166 (Pubitemid 47362038)
62. Piomelli D., Feinmark S. J., Cannon P. J., Leukotriene biosynthesis by canine and human coronary arteries Journal of Pharmacology and Experimental Therapeutics 1987 241 3 763 770
63. De Caterina R., Mazzone A., Giannessi D., Sicari R., Pelosi W., Lazzerini G., Azzara A., Forder R., Carey F., Caruso D., Galli G., Mosca F., Leukotriene B 4 production in human atherosclerotic plaques Biomedica Biochimica Acta 1988 47 10-11 S182 S185
64. Brezinski D. A., Nesto R. W., Serhan C. N., Angioplasty triggers intracoronary leukotrienes and lipoxin A4: impact of aspirin therapy Circulation 1992 86 1 56 63
65. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., Samani N. J., Gudmundsson G., Grant S. F. A., Thorgeirsson G., Sveinbjornsdottir S., Valdimarsson E. M., Matthiasson S. E., Johannsson H., Gudmundsdottir O., Gurney M. E., Sainz J., Thorhallsdottir M., Andresdottir M., Frigge M. L., Topol E. J., Kong A., Gudnason V., Hakonarson H., Gulcher J. R., Stefansson K., The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke Nature Genetics 2004 36 3 233 239 (Pubitemid 38282747)
66. Lefebvre B., Pépin J. L., Baguet J. P., Tamisier R., Roustit M., Riedweg K., Bessard G., Lvy P., Stanke-Labesque F., Leukotriene B 4: early mediator of atherosclerosis in obstructive sleep apnoea? European Respiratory Journal 2008 32 1 113 120
67. Stanke-Labesque F., Bck M., Lefebvre B., Tamisier R., Baguet J. P., Arnol N., Lévy P., Pépin J. L., Increased urinary leukotriene E 4 excretion in obstructive sleep apnea: effects of obesity and hypoxia Journal of Allergy and Clinical Immunology 2009 124 2 364 370.e2
68. Bck M., Hlawaty H., Labat C., Michel J. B., Brink C., The oral cavity and age: a site of chronic inflammation? PLoS One 2007 2 12
69. Bck M., Airila-Mnsson S., Jogestrand T., Sder B., Sder P. O., Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis Atherosclerosis 2007 193 2 389 394 (Pubitemid 47058102)
70. Hakonarson H., Thorvaldsson S., Helgadottir A., Gudbjartsson D., Zink F., Andresdottir M., Manolescu A., Arnar D. Q., Andersen K., Sigurdsson A., Thorgeirsson G., Jonsson A., Agnarsson U., Bjornsdottir H., Gottskalksson G., Einarsson A., Gudmundsdottir H., Adalsteinsdottir A. E., Gudmundsson K., Kristjansson K., Hardarson T., Kristinsson A., Topol E. J., Gulcher J., Kong A., Gurney M., Thorgeirsson G., Stefansson K., Effects of a 5-lipoxygenase- activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial Journal of the American Medical Association 2005 293 18 2245 2256 (Pubitemid 40629191)
71. Allayee H., Hartiala J., Lee W., Mehrabian M., Irvin C. G., Conti D. V., Lima J. J., The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics Chest 2007 132 3 868 874
72. Tardif J. C., L'Allier P. L., Ibrahim R., Grégoire J. C., Nozza A., Cossette M., Kouz S., Lavoie M. A., Paquin J., Brotz T. M., Taub R., Pressacco J., Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with recent acute coronary syndrome Circulation: Cardiovascular Imaging 2010 3 3 298 307
73. Ingelsson E., Yin L., Bck M., Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. Journal of Allergy and Clinical Immunology. In press
74. Capra V., Ambrosio M., Riccioni G., Rovati G. E., Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities Current Medicinal Chemistry 2006 13 26 3213 3226 (Pubitemid 44680865)
75. Riccioni G., Capra V., D'Orazio N., Bucciarelli T., Bazzano L. A., Leukotriene modifiers in the treatment of cardiovascular diseases Journal of Leukocyte Biology 2008 84 6 1374 1378 (Pubitemid 352774472)